GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
116 articles in GLP-1 & Metabolic · page 9 of 10
GLP-1s and Kidney Outcomes: The FLOW Trial, Explained
FLOW cut serious kidney events 24% in diabetics with chronic kidney disease. What the trial shows, and what it does not show.
Read →How GLP-1, GIP, and Glucagon Differ
Three hormones, three roles — and the logic behind single, dual, and triple agonist drugs. How GLP-1, GIP, and glucagon actually differ.
Read →GLP-1s and PCOS: What the Research Shows
A 2026 meta-analysis of 11 trials found modest BMI gains but low-certainty evidence on PCOS hormones and cycle regularity.
Read →GLP-1 Receptor Agonists in the Brain: Appetite and Beyond
These drugs act centrally, not just in the gut. What that means for appetite, reward, and the side effects people actually feel.
Read →GLP-1s and Alcohol Use: An Emerging Signal
Anecdotes and early data hint at reduced drinking on GLP-1s. A measured look at a genuinely interesting but still unproven signal.
Read →GLP-1s and Cardiovascular Outcomes Beyond SELECT
SELECT was the landmark, but the cardiovascular story is broader. What the wider trial evidence shows across the GLP-1 class.
Read →Compounded Semaglutide: The Risks and Realities
FDA found patients drew 5-20x the intended dose of compounded semaglutide. What to understand before entering that market.
Read →GLP-1s and Fatty Liver Disease (MASH): The Evidence
A phase 3 trial moved GLP-1 therapy for MASH from frontier to evidence. What ESSENCE actually showed, and what it left open.
Read →Microdosing GLP-1s: Evidence or Anecdote?
Sub-therapeutic GLP-1 dosing is popular online. The controlled evidence behind it is essentially nonexistent — here is why.
Read →GLP-1s for Sleep Apnea: Reading the SURMOUNT-OSA Data
SURMOUNT-OSA cut the apnea-hypopnea index by about 20-24 events an hour versus placebo. A real signal, mediated by weight loss.
Read →GLP-1 Side Effects: What the Trials Report
Nausea leads the list, but the full picture matters. What the controlled trial data actually documents, and at what rates.
Read →The GLP-1 Weight-Loss Plateau, Explained
Why the scale stops moving on a GLP-1, what is happening physiologically, and what the trial data says to expect at the plateau.
Read →